David Bennett1, Antonella Fossi2, Elena Bargagli2, Rosa Metella Refini2, Maria Pieroni2, Luca Luzzi3, Claudia Ghiribelli3, Piero Paladini3, Luca Voltolini3, Paola Rottoli2. 1. Respiratory Diseases and Lung Transplantation Unit, Internal and Specialist Medicine Department, Azienda Ospedaliera Universitaria Senese (AOUS), Viale Bracci n° 16, 2nd Floor, 3rd Building, 53100, Siena, Italy. david.btt@gmail.com. 2. Respiratory Diseases and Lung Transplantation Unit, Internal and Specialist Medicine Department, Azienda Ospedaliera Universitaria Senese (AOUS), Viale Bracci n° 16, 2nd Floor, 3rd Building, 53100, Siena, Italy. 3. Thoracic Surgery Unit, Cardio-Thoracic-Vascular Department, Azienda Ospedaliera Universitaria Senese (AOUS), Siena, Italy.
Abstract
PURPOSE: Lung transplantation (LTX) is nowadays accepted as a treatment option for selected patients with end-stage pulmonary disease. Idiopathic pulmonary fibrosis (IPF) is characterized by the radiological and histologic appearance of usual interstitial pneumonia. It is associated with a poor prognosis, and LTX is considered an effective treatment to significantly modify the natural history of this disease. The aim of the present study was to analyse mortality during the waiting list in IPF patients at a single institution. METHODS: A retrospective analysis on IPF patients (n = 90) referred to our Lung Transplant Program in the period 2001-2014 was performed focusing on patients' characteristics and associated risk factors. RESULTS: Diagnosis of IPF was associated with high mortality on the waiting list with respect to other diagnosis (p < 0.05). No differences in demographic, clinical, radiological data and time spent on the waiting list were observed between IPF patients who underwent to LTX or lost on the waiting list. Patients who died showed significant higher levels of pCO2 and needed higher flows of O2-therapy on effort (p < 0.05). Pulmonary function tests failed to predict mortality and no other medical conditions were associated with survival. CONCLUSIONS: Patients newly diagnosed with IPF, especially in small to medium lung transplant volume centres and in Countries where a long waiting list is expected, should be immediately referred to transplantation, delay results in increased mortality. Early identification of IPF patients with a rapid progressive phenotype is strongly needed.
PURPOSE: Lung transplantation (LTX) is nowadays accepted as a treatment option for selected patients with end-stage pulmonary disease. Idiopathic pulmonary fibrosis (IPF) is characterized by the radiological and histologic appearance of usual interstitial pneumonia. It is associated with a poor prognosis, and LTX is considered an effective treatment to significantly modify the natural history of this disease. The aim of the present study was to analyse mortality during the waiting list in IPF patients at a single institution. METHODS: A retrospective analysis on IPF patients (n = 90) referred to our Lung Transplant Program in the period 2001-2014 was performed focusing on patients' characteristics and associated risk factors. RESULTS: Diagnosis of IPF was associated with high mortality on the waiting list with respect to other diagnosis (p < 0.05). No differences in demographic, clinical, radiological data and time spent on the waiting list were observed between IPF patients who underwent to LTX or lost on the waiting list. Patients who died showed significant higher levels of pCO2 and needed higher flows of O2-therapy on effort (p < 0.05). Pulmonary function tests failed to predict mortality and no other medical conditions were associated with survival. CONCLUSIONS:Patients newly diagnosed with IPF, especially in small to medium lung transplant volume centres and in Countries where a long waiting list is expected, should be immediately referred to transplantation, delay results in increased mortality. Early identification of IPF patients with a rapid progressive phenotype is strongly needed.
Authors: Roland M du Bois; Carlo Albera; Williamson Z Bradford; Ulrich Costabel; Jonathan A Leff; Paul W Noble; Steven A Sahn; Dominique Valeyre; Derek Weycker; Talmadge E King Journal: Eur Respir J Date: 2013-12-05 Impact factor: 16.671
Authors: Thomas J Richards; Naftali Kaminski; Fred Baribaud; Susan Flavin; Carrie Brodmerkel; Daniel Horowitz; Katherine Li; Jiin Choi; Louis J Vuga; Kathleen O Lindell; Melinda Klesen; Yingze Zhang; Kevin F Gibson Journal: Am J Respir Crit Care Med Date: 2012-01-01 Impact factor: 21.405
Authors: D Castria; R M Refini; E Bargagli; F Mezzasalma; C Pierli; P Rottoli Journal: Int J Immunopathol Pharmacol Date: 2012 Jul-Sep Impact factor: 3.219
Authors: Ganesh Raghu; Harold R Collard; Kevin J Anstrom; Kevin R Flaherty; Thomas R Fleming; Talmadge E King; Fernando J Martinez; Kevin K Brown Journal: Am J Respir Crit Care Med Date: 2012-04-13 Impact factor: 21.405
Authors: T M Egan; S Murray; R T Bustami; T H Shearon; K P McCullough; L B Edwards; M A Coke; E R Garrity; S C Sweet; D A Heiney; F L Grover Journal: Am J Transplant Date: 2006 Impact factor: 8.086
Authors: Brett Ley; Christopher J Ryerson; Eric Vittinghoff; Jay H Ryu; Sara Tomassetti; Joyce S Lee; Venerino Poletti; Matteo Buccioli; Brett M Elicker; Kirk D Jones; Talmadge E King; Harold R Collard Journal: Ann Intern Med Date: 2012-05-15 Impact factor: 25.391
Authors: Talmadge E King; Williamson Z Bradford; Socorro Castro-Bernardini; Elizabeth A Fagan; Ian Glaspole; Marilyn K Glassberg; Eduard Gorina; Peter M Hopkins; David Kardatzke; Lisa Lancaster; David J Lederer; Steven D Nathan; Carlos A Pereira; Steven A Sahn; Robert Sussman; Jeffrey J Swigris; Paul W Noble Journal: N Engl J Med Date: 2014-05-18 Impact factor: 91.245
Authors: Alejandro Robles-Perez; Jordi Dorca; Ivan Castellví; Joan Miquel Nolla; Maria Molina-Molina; Javier Narváez Journal: Rheumatol Int Date: 2020-03-10 Impact factor: 2.631
Authors: L Paglicci; V Borgo; N Lanzarone; M Fabbiani; C Cassol; M G Cusi; M Valassina; S Scolletta; E Bargagli; L Marchetti; P Paladini; L Luzzi; A Fossi; D Bennett; F Montagnani Journal: Eur J Clin Microbiol Infect Dis Date: 2021-01-21 Impact factor: 3.267
Authors: Marek Ochman; Maciej Urlik; Zofia Tatoj; Fryderyk Zawadzki; Marta Wajda-Pokrontka; Magdalena Latos; Piotr Przybyłowski; Marian Zembala Journal: Arch Med Sci Date: 2019-01-30 Impact factor: 3.318